Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

93.19
+3.263.63%
Post-market: 93.190.00000.00%19:30 EDT
Volume:1.24M
Turnover:114.72M
Market Cap:8.22B
PE:-46.36
High:95.27
Open:91.16
Low:90.48
Close:89.93
52wk High:110.18
52wk Low:15.86
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.96
T/O Rate:1.53%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.61
PE(LYR):-47.17

Loading ...

Spyre Therapeutics CFO Scott L. Burrows Disposes of USD 1.85 Million in Common Shares

Reuters
·
5 hours ago

Spyre Therapeutics Grants Inducement Equity Awards of 21,424 Stock Options and 6,604 RSUs to New Hires

Reuters
·
11 hours ago

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
11 hours ago

Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121

THOMSON REUTERS
·
Oct 01

Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial

THOMSON REUTERS
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Movement Alert|SPYRE THERAPEUTICS INC Rises 6.21% in Regular Trading, Trading at $89.915

Market Focus
·
Sep 30

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Sep 28

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Sep 09

Spyre Therapeutics (SYRE) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Sep 09

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

TIPRANKS
·
Sep 09

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

MT Newswires Live
·
Sep 08

Spyre Therapeutics announces 12-week induction data from Part A of SKYLINE trial

TIPRANKS
·
Sep 08

Spyre Reports Positive Phase 2 Skyline Part a Induction Data for UC Drug Spy003, Hits Primary Endpoint

Reuters
·
Sep 08

Spyre Therapeutics - Spy003 Meets Primary Endpoint with 10.0-Point Rhi Reduction at Week 12

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics - Spy003 Well Tolerated with Safety Profile Consistent with Il-23 Class

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics - Spy003 Achieves 20% Clinical Remission and 30% Endoscopic Improvement at Week 12

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics - Skyline Part B Enrolling; Topline Induction Data Expected in 2027

THOMSON REUTERS
·
Sep 08

Spyre Therapeutics Grants Inducement Awards of 2,106 Stock Options, 745 RSUs to New Employee

Reuters
·
Sep 05

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Sep 05